Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Transmed Gothenburg AB shows 1 pending office action within the Biotechnology & Pharmaceuticals technology area. Prosecution is currently limited to 1 distinct examiner, MORGAN, BAILEY MICHELLE. The company's active matters are located in 1 distinct art unit, suggesting a specific technical focus for the pending pharmaceutical application. This arrangement ensures that the examination process remains within a single administrative group, which can lead to a more predictable sequence of office actions.
The busiest examiner, MORGAN, BAILEY MICHELLE, is responsible for 1 pending office action. With 1 distinct examiner handling the 1 pending action, the prosecution process is streamlined under a single reviewer. This allows the company to focus its resources on the specific feedback from this examiner within the biotechnology domain. The busiest examiner pending count of 1 indicates that the company's current patent strategy is entirely focused on the feedback and examination style of this single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998693 | FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY | MORGAN, BAILEY MICHELLE | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998693 | FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY | MORGAN, BAILEY MICHELLE | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998693 | FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY | MORGAN, BAILEY MICHELLE | 1645 | §102§103 | Final Rejection | 30d overdue | Pending | Nov 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial